Feb 20 |
Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss
|
Feb 13 |
After Plunging -15.61% in 4 Weeks, Here's Why the Trend Might Reverse for Veru Inc. (VERU)
|
Feb 9 |
Veru Inc. (NASDAQ:VERU) Q1 2024 Earnings Call Transcript
|
Feb 9 |
Q1 2024 Veru Inc Earnings Call
|
Feb 8 |
Veru Inc. (VERU) Q1 2024 Earnings Call Transcript
|
Feb 8 |
Veru reports Q1 results
|
Feb 8 |
Veru Reports Fiscal 2024 First Quarter Financial Highlights
|
Feb 7 |
Veru Q1 2024 Earnings Preview
|
Feb 6 |
Veru eyes better weight loss drugs as FDA clears Phase 2 trial
|
Feb 6 |
Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs
|